Analyst Sees Further Pfizer Bid On AstraZenica 'Highly Likely'

Loading...
Loading...
Pfizer Inc.
PFE
is likely to boost its offer for British drug maker AstraZenica
AZN
to $96.28 a share, an analyst said Tuesday. SunTrust's John Boris said a deal would cut Pfizer's tax rate to 20 percent and said potential Treasury inversion action blocking such action is merely “election year rhetoric.” The $127 billion offer envisioned by Boris would tack on 6.3 percent to its earlier bid of $120 billion takeover offer, which AstraZenica rejected back in mid-May AstraZeneca's American Depositary Receipts were recently down 2 percent at $74.62 from Friday's high but were still up nearly 26 percent for the year. Under British rules, AstraZeneca can starting Tuesday invite it back for talks or Pfizer can make a single "knock-out" bid which it believes would be accepted. Or Pfizer can start a more conventional bidding process over again beginning in November.
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst ColorNewsRumorsM&AAnalyst Ratings
We simplify the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...